TCA
MRNA icon

Transcend Capital Advisors’s Moderna MRNA Stock Holding History

Transcend Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,200
Closed -$260K – 514
2022
Q3 		$260K Buy
2,200
+33
+2% +$5.01K 0.03% 390
2022
Q2 		$310K Buy
+2,167
New +$310K 0.03% 373
2022
Q1 		– Sell
-4,706
Closed -$1.2M – 535
2021
Q4 		$1.2M Buy
4,706
+328
+7% +$95.9K 0.11% 195
2021
Q3 		$1.51M Buy
+4,378
New +$1.61M 0.14% 166

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Transcend Capital Advisors's MRNA Position: Q4 2022 in Review

Transcend Capital Advisors sold out of Moderna (MRNA) in Q4 2022, closing a stake of 2,200 shares — an estimated $260K sold.

Transcend Capital Advisors first reported a position in MRNA in Q3 2021 and held it in 4 quarters. The position peaked at $1.51M in Q3 2021. 1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Transcend Capital Advisors reported no remaining Moderna position as of Q4 2022 after selling out during the quarter.
  • Transcend Capital Advisors sold 2,200 Moderna shares in Q4 2022, an estimated $260K.
  • Transcend Capital Advisors first reported a position in Moderna in Q3 2021 and held it in 4 quarters.
  • Transcend Capital Advisors's Moderna position peaked at $1.51M in Q3 2021.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Transcend Capital Advisors's 13F filing for Q4 2022, filed 20 Jan 2023.